Priming of naive CD8 T cells by dendritic cells (DCs) entails both effective antigen presentation on MHC class I products and co-stimulatory signaling. Their optimal coupling is a major goal in the development of CTL-inducing vaccines. We recently reported that a membranal derivative of the invariant MHC-I light chain, b 2 -microglobulin (b 2 m), markedly stabilizes MHC-I molecules and can serve as a universal platform for exceptional presentation of genetically linked peptides. To test whether it is possible to equip the resulting MHC-I complexes with an inherent ability to activate antigen-presenting cells, we engrafted the intracellular Toll/IL-1 receptor domain of mouse Toll-like receptor (TLR) 4 or TLR2 onto the peptide-b 2 m scaffold. We evaluated the level of peptide presentation and status of cell activation conferred by such constructs in stably transfected mouse RAW264.7 macrophages and mRNA-transfected mouse DC2.4 DCs. We show that the encoded peptide-b 2 m-TLR polypeptides are expressed at the cell surface, pair with endogenous heavy chains, stabilize MHC-I products, prompt efficient peptide-specific T-cell recognition and confer a constitutively activated phenotype on the transfected cells, as judged by the up-regulation of proinflammatory genes and surface co-stimulatory molecules. Our results provide evidence that the product of a single recombinant gene can couple MHC peptide presentation to TLR-mediated signaling and offer a safe, economical and highly versatile modality for a novel category of genetic CTL-inducing vaccines.
Introduction
The development of effective CTL-inducing vaccines is a long sought-after goal, especially in the field of cancer immunotherapy. Priming of CTL precursors (CTLp) is mediated in secondary lymphoid organs, primarily by dendritic cells (DCs). These provide CTLp with an adequate antigenic stimulus in the form of MHC-I-bound peptides and deliver an array of co-stimulatory signals. Autologous DCs have therefore been widely explored in recent years as a cellular vehicle for the induction of antigen-specific CTLs (1) (2) (3) (4) (5) (6) (7) .
Bone marrow (BM)-derived DC precursors migrate from the blood to various tissues and acquire an immature DC phenotype. These cells can capture invading pathogens or their constituents through both receptor-mediated and non-receptor-mediated pathways and cross-present their degradation products in the form of MHC-I-bound peptides. Loading of protein antigens or delivery of antigencoding genes to DCs allows efficient MHC-I peptide presentation, which can be significantly improved by rational targeting of the protein products to distinct subcellular compartments along the MHC-I processing and presentation pathway (8) . In order to prime CTLp, DCs must first be activated by pathogen-or stress-associated molecular determinants, many of which are recognized by members of the Toll-like receptor (TLR) family (9) . The particular TLRs that are engaged at the DC surface polarize the ensuing adaptive response toward the T h 1, T h 2 or the regulatory T-cell course. The appreciation that distinct TLRs can modulate T-cell response has made a tremendous impact on the formulation of TLR agonists so as to enhance vaccine efficacy and this notion is widely implemented in current vaccine design (10) (11) (12) . However, potential toxicity and unpredictable pleiotropic effects currently limit the systemic administration of TLR agonists as adjuvants (13) .
In the past several years, we have been exploring the MHC-I light chain, b 2 -microglobulin (b 2 m), as a novel genetic platform for the induction of antigen-specific CTLs. To this end, we have converted b 2 m into an integral membranal protein, while genetically linking antigenic peptides to its N-terminus (14) (15) (16) . This modality bypasses the main bottlenecks in the conventional MHC-I processing and presentation pathway and prompts exceptionally efficient MHC-I presentation of the linked peptides. The monomorphic nature of b 2 m renders this scaffold universal, useful for presenting peptides restricted by the myriad of different HLA-I products. To evaluate this approach in a mouse melanoma model we recently used as antigen-presenting cells (APCs) stably-transfected TAP-deficient RMA-S cells expressing two tumor-associated peptides fused to membrane-anchored b 2 m (16) . Indeed, these cells were superior to peptide-loaded cells in eliciting tumor-specific CTLs, conferring long-lasting tumor protection and inhibiting the growth of pre-established tumors.
We realized that endowing membranal peptide-b 2 m with the concomitant ability to activate transfected APCs can couple MHC-I presentation to co-stimulation and substantially improve the immunological performance of such vaccines. It is well established that truncated Toll or TLRs, devoid of their ligand-binding domain, signal constitutively, thus acting in a dominant-positive fashion (17, 18) . The use of mRNA transfection for immuno-gene therapy by a simple electroporation protocol is safe, simple and extremely efficient and is becoming the tool of choice for various applications (19, 20) . In a number of recent studies, transfection of DCs with mRNA encoding constitutively active TLR4 (caTLR4) could provide tumor-specific CD8 T cells with costimulatory signals that were necessary for mounting an effective anti-tumor response (21) (22) (23) (24) .
In this study, we took advantage of these notions and genetically linked the extracellular peptide-b 2 m fusion component to the intracellular TLR-signaling portion known as the Toll/IL-1 receptor (TIR) domain. We focused on two members of the mouse TLR family, TLR4 and TLR2, which naturally localize to the plasma membrane. We examined different structural and functional aspects of the engraftment of the TIR domain of these TLRs onto the b 2 m scaffold in the form of peptide-b 2 m-TIR, employing two mouse APC lines: RAW264.7 macrophages and DC2.4 DCs. We provide evidence that efficient presentation of the linked peptide can be coupled to constitutive TLR signaling through the polypeptide product of a single gene and that this dual effect can be achieved by virtue of mRNA electroporation. . The TLR2 ligand zymosan was from InvivoGen (San Diego, CA, USA) and was used at 0.1 mg ml
Methods

Cell lines
RAW264.7 is a BALB
À1
.
Vectors and expression plasmids
The pGEM-T vector for direct cloning of PCR products and the pCI-Neo expression vector were from Promega (Madison, WI, USA). The pBJ1-Neo expression vector was previously described (29) . ThepEGFP-N3 vector for the expression of EGFP fusion proteins was from Clontech (Palo Alto, CA, USA). Template DNA for in vitro transcription of mRNA was cloned in the pGEM4Z/GFP/A64 vector [(30), a kind gift from Dr E. Gilboa, University of Miami, FL] following the removal of the GFP insert (pGEM4Z/A64). The transmembrane and cytoplasmic portion of mouse TLR4 (mTLR4, positions 624-835 according to GenBank accession AF110133) was produced by reverse transcriptase (RT)-PCR as a SalI-NotI fragment from mRNA of RAW264.7 cells with the forward primer: 5#-CCGTCGACCACCTGTTATATGTACAAGACAATC-3# and the reverse primer: 5#-CGCGCGGCCGCACTGGGTTTAGGCCC-CAG-3#. The tc portion of mTLR2 (positions 589-784 in GenBank accession BC014693) was cloned by RT-PCR from RAW264.7 mRNA as an XhoI-NotI fragment with the forward primer: 5#-CCCTCGAGCGCACTGGTGTCTGGAGTC-3# and the reverse primer: 5#-CGCGCGGCCGCAGGAAGTCAG-GAACTGGG-3#. Generation of the XhoI-NotI fragment coding for the tc part of H-2K b as well as the full hb 2 m-H-2K b construct was previously described (15) . For the assembly of the genes encoding hb 2 m-TLR4/2, the H-2K b portion in hb 2 m-H-2K b was replaced with that of the respective TLR. An XbaI-BamHI fragment encoding the full leader peptide of mouse b 2 m, the G9V peptide and the 5# part of the flexible linker Gly 4 Ser(Gly 3 Ser) 2 was cloned essentially as in (14) (15) (16) . The OVA 257-264 -hb 2 m-H-2K b construct was previously described (16) . For creating the intact constructs encoding peptide-hb 2 m-anchor, all corresponding fragments were modularly cloned in a single step. DNA sequence of all PCR-generated products was verified.
In vitro mRNA transcription
Template DNA cloned in the pGEM4Z/A64 vector was prepared with the EndoFree Plasmid Maxi Kit (Qiagen, Valencia, CA, USA) and linearized via the SpeI restriction site positioned at the 3# end of the poly (A) tract of the vector. One microgram of linear plasmid was used for in vitro mRNA transcription with AmpliCap-Max T7 High Yield Message Maker Kit (Epicentre Biotechnologies, Madison, WI, USA). The concentration and quality of the mRNA were assessed by spectrophotometry and agarose gel electrophoresis.
DNA and RNA transfection
For DNA, plasmid was prepared with the EndoFree Plasmid Maxi Kit. RAW264.7 cells (0.8 ml) at 8 3 10 6 cells ml À1 were mixed in a 4-mm sterile electroporation cuvette with 10 lg DNA. Transfection was performed with Gene Pulser Xcell (Bio-Rad Laboratories, Hercules, CA, USA) at 350 V, 960 lF. Cells were re-suspended in fresh medium and cultured for 24-48 h in 96-well plates before the addition of G418 to a final concentration of 1 mg ml À1 . For mRNA, 3 3 10 6 DC2.4 cells were washed twice with OptiMEM medium (Gibco BRL, Grand Island, NY, USA). Cells were re-suspended in 200 ll OptiMEM containing 5 lg in vitro-transcribed mRNA (in most experiments) and electroporated using ECM 830 electroporation apparatus (BTX/Harvard Apparatus, Holliston, MA, USA) at LV mode, 300 V, 3 ms, one pulse. Cells were re-suspended in 5 ml growth medium and transferred into six-well plates for incubation.
Flow cytometry
One million cells were harvested and washed twice using 2 ml FACS buffer (5% FCS, 0.05% sodium azide in PBS). For indirect staining, cells were stained with 1 lg ml À1 of primary antibody for 1 h at 4°C, washed twice with FACS buffer and stained with 1 lg ml À1 of FITC-labeled secondary antibody for 1 h at 4°C. Cells were washed twice, re-suspended in 1 ml cold PBS and analyzed by FACSCalibur (Becton Dickinson, San Jose, CA, USA). For direct staining, cells were washed once in cold FACS buffer, transferred into FACS tubes and antibodies were added. Cells were incubated for 30 min at 25°C in the dark and washed once using 3 ml FACS buffer, re-suspended in 0.5 ml PBS with 0.1% sodium azide and analyzed by flow cytometry, using FlowJo software (ThreeStar, San Carlos, CA, USA).
Semiquantitative RT-PCR
Total RNA from 5 3 10 6 cells was purified using the TRI Reagent (Sigma). One microgram of total RNA was used for cDNA synthesis with AMV RT (Promega). PCR was performed with the following primers: IL-1b forward: 5#-TGAAATGC-CACCTTTTGACA-3# and IL-1b reverse: 5#-AGGCCACAGG-TATTTTGTCG-3#; tumor necrosis factor (TNF) a forward: 5#-GGCAGGTCTACTTTGGAGTCATTGC-3# and TNFa reverse: 5#-ACATTCGAGGCTCCAGTGAATTCGG-3#; cyclooxygenase 2 (COX2) forward: 5#-TTCAAAAGAAGTGCTGGAAAAGGT-3# and COX2 reverse: 5#-GATCATCTCTACCTGAGTGTCTTT-3# and GAPDH forward: 5#-GGCATTGCTCTCAATGACAA-3# and GAPDH reverse: 5#-TGTGAGGGAGATGCTCAGTG-3#.
T-cell hybridoma activation assay
Sixty thousand hybridoma cells were incubated with serial dilutions of the respective APC (transfected or loaded with synthetic peptide) in 96-well plates for 12 h. Growth medium was removed and 100 ll of lysis buffer [9 mM MgCl 2 , 0.125% NP-40, 0.3 mM chlorophenol red b-D galactopyranoside (CPRG) in PBS] was added to each well. One hour post-lysis, the optical density (OD) of each well was monitored with a Synergy HT Multi-Mode Microplate reader (BioTek, Winooski, VT, USA) at 570 nm, with 630 nm as reference.
Immunoprecipitation
Sixty million cells were harvested by centrifugation, washed twice with PBS, re-suspended in cold lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 1 mM phenylmethylsulphonylfluoride, 1 lg ml À1 aprotinin, 1 lg ml À1 leupeptin) and incubated for 25 min on ice with gentle agitation. Pellet was removed by centrifugation (10 000 3 g, 10 min, 4°C) and cell lysate was kept at À20°C. For pre-clearing of lysates, 20 ll protein G agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were washed twice in lysis buffer and incubated with lysate for 1 h at 4°C with gentle agitation. Lysate was separated from the beads by centrifugation (12 000 3 g, 10 min, 4°C) and incubated with 10 lg of F9-18-10 antibody overnight at 4°C with gentle agitation. Twenty-five microliters of beads were washed twice with lysis buffer, added to the antibody-lysate mixture and incubated for 1 h at 4°C with gentle agitation. Following five washing cycles with lysis buffer by centrifugation at 12 000 3 g, 1 min, 4°C, bound proteins were eluted from the beads with 31 Lammeli sample buffer. The precipitated proteins were kept at À20°C.
Western blot analysis
Samples were boiled for 5 min and were subjected to SDS-PAGE at 50 mA. Separated proteins were transferred onto a nitrocellulose membrane. Themembrane was blocked with milk buffer [5% milk powder in TPBS (0.05% Tween 20 in PBS)] overnight at 4°C and 1 h at room temperature. The membrane was then washed twice with PBS and incubated Coupling MHC-I presentation to APC activation 455 for 2 h with the primary antibody and washed six times (36 min) with TPBS and incubated for 1 h with the secondary peroxidase-conjugated antibody. The membrane was then washed three times (310 min) with TPBS and then developed with an ECL kit (Pierce, Rockford, IL, USA).
Lysosomal degradation
DC2.4 cells were electroporated with 10 lg mRNA as described above and immediately transferred into warm growth medium with/without 30 lM chloroquine. Seven hours post-electroporation, cells were harvested, re-suspended in cold lysis buffer and incubated for 25 min in ice with gentle agitation. Lysates were subjected to western blot analysis using anti-hb 2 m and anti-GAPDH mAbs as reference.
DC2.4 maturation
Three million DC2.4 cells were electroporated with 5 lg of the respective mRNA. As positive control for maturation DC2.4 cells were incubated for 24 h with 1 lg ml À1 LPS. Peptide-loaded and non-treated DC2.4 cells served as positive control for presentation and negative control for maturation, respectively. Twenty-four hours post-electroporation, cells were analyzed by flow cytometry for the surface expression of co-stimulatory molecules.
Results
Gene assembly and expression
In order to test whether a genetically linked peptide can couple MHC-I presentation to constitutive cellular activation, we generated two series of b 2 m-based constructs (Fig. 1) . We took advantage of the modular-cloning format we had previously established for the b 2 m platform [(14-16), Fig.  1A ] and replaced the transmembranal and cytosolic domains of H-2K b with the intact transmembranal and cytosolic domains of native TLR4 or TLR2. We have included a number of amino acids from the extracellular domain of each as a part of the bridge segment, making sure to preserve the total length of 13 amino acids that spans the distance between the C-terminus of b 2 m and the plasma membrane (31) . In order to easily detect the protein product on the surface of transfected mouse APCs, we have employed hb 2 m, which pairs efficiently with all mouse MHC-I heavy chain and linked either B15-23(G9V), the higher affinity derivative of the H-2K d -binding mouse insulin b chain B15-23 peptide (28, 32) , the H-2D b -binding peptide human gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] or the H-2K b -binding peptide from chicken ovalbumin, OVA [257] [258] [259] [260] [261] [262] [263] [264] . Composition of all clones and their designation are detailed in Fig. 1(C) .
Dual function of peptide-b 2 m-TLR in stably transfected RAW264.7 cells
The mouse insulin B15-23(G9V)-coding constructs were used to generate stable transfectants of the murine RAW264.7 macrophage cell line. A flow cytometry analysis for surface expression of hb 2 m and H-2K d in representing clones is shown in Fig. 2 . The expression hierarchy revealed by the flow cytometry analysis of hb 2 m is InK b >InTLR2%InTLR4 ( Fig. 2A) , while H-2K d expression is substantially higher in InTLR4 and InK b , and to a lesser extent in InTLR2 transfectants compared with InTLR2 and RAW264.7 (Fig. 2B) .
To confirm that the polypeptide products indeed associate at the cell surface with the endogenous H-2K d heavy chain, we performed a co-immunoprecipitation analysis (Fig. 2C) . H-2K d molecules were precipitated from cell lysates and subjected to SDS-PAGE analysis for the presence of hb 2 mbearing polypeptides. Indeed, products of the expected size were detected in transfectants expressing InTLR4, InTLR2 and InK b but not in parental RAW264.7 cells, while crossreactivity with mouse b 2 m could detect the endogenous light chain in all four samples.
We then assessed H-2K d presentation of the linked peptide by the three transfectants by evaluating their ability to activate the CHIB2 T-cell hybridoma (28, 32) . This hybridoma is specific to the H-2K d -B15-23 complex and the NFAT-lacZ reporter gene allows detection of T-cell activation by a simple colorimetric assay for b-Gal activity. As shown in Fig. 3(A) , the stimulatory capacity of InTLR4, InTLR2 and InK b was superior to that of parental RAW264.7 cells loaded with a saturating amount of the synthetic peptide (Fig. 3B) , while untreated RAW264.7 cells exhibited no activity, as expected. Of note, InTLR4, InTLR2 and InK b were repeatedly far superior to the peptide-loaded cells in their ability to activate CHIB2. These results are consistent with our previous work, which demonstrated that membrane-anchored b 2 m exerts a marked stabilization effect on MHC-I molecules (15) .
Next, we addressed the functional properties of the TLR moieties in these constructs by comparing the activation status of the InTLR4 and InTLR2 transfectants with that of the InK b -expressing clone. For this purpose, we performed a semiquantitative (sq) RT-PCR analysis for the basal level of mRNA encoding the pro-inflammatory products, TNFa and COX2 (Fig. 3C) . The analysis of both products clearly reveals that the expression of InTLR4 and InTLR2 in RAW264.7 results in marked up-regulation of these two genes. While InK b did not exert any detectable effect on TNFa mRNA, a certain increase was observed for COX2, although considerably lower than that mediated by InTLR4 and InTLR2. Taken together, the results of the last three experiments demonstrate efficient coupling of peptide presentation to APC activation through a single polypeptide product.
Peptide-b 2 m-TLR constructs are active in mRNA-transfected DC2.4 DCs
Delivery of antigen-encoding mRNA to autologous DCs emerges in recent year as a safe and efficient modality for CTL induction, particularly in the field of cancer immunotherapy. We therefore went on to evaluate the peptide-b 2 m-TLR design in mRNA-transfected DCs. The experimental system we devised for this purpose comprises the C57BL/6 (H-2 b )-derived DC line DC2.4 (25) , the H-2K b -binding peptide OVA 257-264 and the H-2D b -binding peptide human gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] . Using our modular cloning scheme, we employed the pGEM4Z/A64 vector to generate templates for in vitro transcription of mRNA encoding OvK b , OvTLR4, OvTLR2, gpTLR4 and gpTLR2.
Persistence of antigenic peptides presented on MHC-I by the priming DCs is a key parameter that influences the magnitude and quality of the ensuing CTL response (33) . We therefore compared the duration of OVA 257-264 presentation by these DCs by measuring the surface levels of K b -OVA 257-264 complexes and total H-2K b at 6-72 h posttransfection. DCs were electroporated with mRNA-encoding OvK b , OvTLR4 and OvTLR2. As positive control, DCs were pre-loaded with a saturating concentration of OVA [257] [258] [259] [260] [261] [262] [263] [264] and analyzed for presentation by flow cytometry using a complex-specific mAb. While OvDC2.4 lost detectible OVA 257-264 presentation already after 24 h, marked presentation of the peptide at that time point was still evident for all mRNA-transfected cells (Fig. 4A) . Moreover, OvK b as well as the two mixtures prompted robust presentation for >48 h. Of note, at 48 h, post-electroporation presentation by these three transfectants was comparable to that observed for peptide-loaded cells at 6 h. All transfectants expressing membranal b 2 m, including OvK b , exhibited pronounced and durable elevation in the level of surface H-2K b (Fig. 4B ), in accord with the results presented in Fig. 3A .
Complexes formed at the cell surface between TLR4 and its LPS ligand endocytose by a receptor-mediated mechanism and localize to endosomal/lysosomal compartments prior to their degradation (34, 35) . To address endocytic degradation of OvTLR4, we have used the lysosomotropic agent chloroquine, which inhibits maturation of early endosomes to lysosomes and subsequent degradation of internalized substances by disrupting vesicular acidification. We transfected DC2.4 cells with OvTLR4 or OvK b mRNA and treated the transfected cells with chloroquine. Western blot analysis for the level of the protein products in whole cell lysates shows that chloroquine raised the level of OvTLR4 but had no apparent effect on OvK b (Fig. 4C ). This result suggests that the truncated TLR4 moiety in this construct induces internalization and subsequent endocytic degradation, in accord with the natural route of TLR4 following engagement with LPS at the cell surface.
We then went on to evaluate the ability of the TLR4 and TLR2 moieties to constitutively activate DC2.4 cells. We first tried to identify maturation markers that are up-regulated following activation with LPS. In spite of repeated attempts, no elevation in the level of the archetypal DC activation markers CD80, CD86 or MHC-II could be detected by flow cytometry analysis (data not shown). The only significant increase was observed for CD40. We therefore electroporated DC2. (Fig. 5A ). OvTLR4 and gpTLR4 mRNA, but none of the other constructs triggered pronounced elevation of CD40, while no treatment, including LPS, could induce significant change in the basal level of CD86 (Fig. 5B) . The sqRT-PCR analysis indicates that OvTLR4 and OvTLR2, but not OvK b , constitutively induced up-regulation of pro-inflammatory genes in DC2.4 cells (Fig. 5B) . Taken together with their ability to efficiently present OVA 257-264 , OvTLR4 and OvTLR2 mRNAs evidently accomplish the dual task of APC activation and peptide 6 of each of the indicated cells were incubated with anti-H-2K d mAb and precipitated using protein G-coated agarose beads. The precipitated products were subjected to non-reduced SDS-PAGE analysis and specific proteins were detected with rabbit polyclonal antibodies to hb 2 m and horseradish peroxidase-conjugated goat anti-rabbit IgG (H + L) antibodies. The membrane was developed by ECL.
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Discussion
In this study, we evaluated the in vitro performance of a novel category of bifunctional genetic vaccines designed to elicit peptide-specific CD8 T-cell responses. These vaccines utilize membrane-anchored b 2 m as their backbone, so that the polypeptide product carries an antigenic peptide of choice linked to the N-terminus of b 2 m and a cytosolic TIR domain of a selected TLR fused to its C-terminus. This structure was devised to maximize and prolong MHC-I presentation of the linked peptide by gene-modified APCs while transmitting activation signals to the cell nucleus in a ligand-independent manner. The bipartite product guarantees that both functions are executed by the same APC, thus focusing and maximizing the expected CTLp priming capacity. The economy offered by this design pertains to all methodologies in which the number of therapeutic (and accessory) genes that can be incorporated into a single vector is a limiting factor. Minimizing the number of genes is also expected to reduce labor and time associated with vaccine preparation and administration, regardless of the actual protocol.
In fact, presentation of the genetically linked peptides as reported here can be solely attributed to the conventional MHC-I processing and presentation pathway. Although we did not address this issue directly in this study, the outstanding presentation level of both insulin B15-23(G9V) (Fig. 3A) and OVA [257] [258] [259] [260] [261] [262] [263] [264] (Fig. 4B) , which exceeds that of exogenous peptide provided at saturating conditions, rules out this possibility. Inprevious works, we examined this question by using complex-specific mAbs for quantitative analysis of surface MHC-I complexes (14, 16) , co-immunoprecipitation analysis and proteasome inhibition (H. Noy, A. M., G. G., unpublished results) and TAP-deficient RMA-S cells (16) . All these experiments clearly indicated that the b 2 m-bound peptide, rather than the conventional pathway, is the principal . Cells were then lysed and b-Gal enzymatic activity was monitored with CPRG. Results are presented as OD. (C) sqRT-PCR analysis for the basal level of TNFa and COX2 mRNA. RT-PCR was performed on mRNA prepared from the indicated transfectants and from parental RAW264.7 cells, either non-treated (NT), as a negative control or treated for 24 h with 1 lg ml À1 LPS or 0.1 mg ml À1 Zymosan, the corresponding ligands of TLR4 and TLR2, as positive controls. Shown is an ethidium bromide-stained agarose gel with RT-PCR samples generated from 1 lg of RNA with sets of primers specific to TNFa (up) or COX2 (down) and GAPDH for normalization. source for the abundant MHC-I complexes at the cell surface. This conclusion is further supported by the increase in the level of the cognate MHC-I product observed in the transfected cells (Figs 2B and 4B) . The fact that the actual MHC-I presentation driven by our platform markedly exceeds saturation with synthetic peptide is another manifestation of the remarkable MHC-I stabilization conferred by the use of membrane-anchored b 2 m (15). Interestingly, this advantage is evident even for OvTLR4 (Fig. 4A) in spite of its apparent internalization and subsequent degradation (Fig. 4C) , underscoring the extent of this phenomenon.
Our design provides an exceptional platform for presenting antigenic peptides delivered to APCs via mRNA, which may be superior to other methods currently under investigation. In spite of the growing interest in using mRNAelectroporated DCs for immunotherapy, mRNA has mainly been applied to enrich DCs with either the total antigenic cargo of tumor cells or a single intact protein of choice (19, 20) . The expanding variety of genetic devices for targeting selected peptides to downstream stations along the MHC-I pathway in order to enhance their presentation (8) has made little impact on the field of mRNA vaccines. Reports describing the rational utilization of mRNA in attempt to influence the activation status of antigen-loaded DCs are scarce, and only few of these works harnessed caTLRs (in all cases caTLR4) for this purpose (21) (22) (23) (24) . Two of these studies (21, 22) used caTLR4 in conjunction with mRNA encoding the intact melanoma-associated antigen Melan-A/MART-1, and the other two used an mRNA mixture coding for a triad of DC-activating molecules: caTLR4, CD40 ligand and CD70, together with either Melan-A/ MART-1 mRNA (23) or whole tumor-antigen-encoding mRNA (24) . Here we show, for the first time, that targeting a selected peptide for MHC-I presentation through mRNA transfection can be exceptionally potent, and in fact superior, both in level and duration, to synthetic peptide-loaded exogenously. In another experimental setting, mRNA encoding peptide-b 2 m-anchor could activate peptide-specific CD8 T cells up to 7 days post-transfection of normally dividing APCs (N. Levin, A. M., G. G., unpublished results).
In mRNA-transfected DC2.4 cells, TLR4 was more potent than TLR2 in up-regulating CD40 expression and sustaining Coupling MHC-I presentation to APC activation 459 longer term induction of pro-inflammatory genes (Fig. 5B  and C) . These findings coincide with the superiority of human caTLR4 over human caTLR2 in triggering NF-jB and up-regulating the promoters of an array of pro-inflammatory genes (36) . It is plausible that this outcome is related to the fact that TLR4 functions primarily in a homodimeric configuration, whereas TLR2-mediated activation often requires either TLR1 or TLR6 as a signaling partner (37) .
Cellular localization of TLRs governs both their mode of signaling and its intensity (38) . In particular, cell surface engagement of TLR4 with LPS induces endocytosis, which terminates MyD88-TIRAP-mediated NF-jB signaling and further production of pro-inflammatory cytokines (34) . Signaling through endocytosed TLR4 in turn initiates the TRIF-TRAM-mediated interferon-response pathway and the synthesis of type 1 interferons (39) and is followed by proteasomal degradation of the complex. The ability of chloroquine to rescue OvTLR4 but not OvK b (Fig. 4C ) supports the notion that truncated TLR4 internalizes in a ligand-independent manner, thus mimicking the effect of LPS-TLR4 complex formation, and is another manifestation of the functionality of caTLR4 in the context of b 2 m.
The H-2K b -derived anchor was more effective than the TLR4 and TLR2 TIR domains in promoting antigen-specific activation of the CHIB2 T-cell hybridoma (Fig. 3A ). Yet, we were unable to associate the expression of the H-2K b anchor with any signaling activity. Unlike the inert H-2K b anchor, TLR2 and TLR4 clearly display autonomous signaling capacity; yet, they were less potent in facilitating peptide presentation. We therefore conclude that the magnitude of T-cell hybridoma activation (Fig. 3A) is solely governed by the expression level. This is not surprising, taking into account the activated/memory phenotype of T-cell hybridomas, which renders them responsive to antigen in the apparent absence of co-stimulatory signaling (26, 32) . At the same time, both TLR domains, which exhibited lower level of expression and presentation compared with H-2K b , were by far more effective than peptide-loaded cells in activating the corresponding T-cell hybridomas. In this context, the marked superiority of mRNA-transfected DC2.4 cells over peptideloaded cells in presenting OVA [257] [258] [259] [260] [261] [262] [263] [264] in spite of the extraordinary affinity of this peptide to H-2K b (Fig. 4A) , underscores the potency of our b 2 m-based platform.
In summary, we provide evidence that the engraftment of caTLR to peptide-b 2 m couples robust and persistent MHC-I presentation to APC activation and suggests that this effect can be achieved via mRNA electroporation of ex vivomanipulated DCs. Several in vivo and ex vivo studies evaluating the efficacy of this approach in the context of mouse and human tumors are currently underway.
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